scholarly journals Molecular Evolution of the Equilibrative Nucleoside Transporter Family: Identification of Novel Family Members in Prokaryotes and Eukaryotes

2002 ◽  
Vol 19 (12) ◽  
pp. 2199-2210 ◽  
Author(s):  
Yugo Acimovic ◽  
Imogen R. Coe
2003 ◽  
Vol 278 (37) ◽  
pp. 35127-35134 ◽  
Author(s):  
Alex Stein ◽  
Gayatri Vaseduvan ◽  
Nicola S. Carter ◽  
Buddy Ullman ◽  
Scott M. Landfear ◽  
...  

2010 ◽  
Vol 285 (27) ◽  
pp. 20827-20833 ◽  
Author(s):  
Megan J. Downie ◽  
Kamal El Bissati ◽  
April M. Bobenchik ◽  
Laura Nic Lochlainn ◽  
Alexander Amerik ◽  
...  

2004 ◽  
Vol 447 (5) ◽  
pp. 735-743 ◽  
Author(s):  
Paul R. Beal ◽  
Sylvia Y. M. Yao ◽  
Stephen A. Baldwin ◽  
James D. Young ◽  
Anne E. King ◽  
...  

2004 ◽  
Vol 383 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Alexandra WORMIT ◽  
Michaela TRAUB ◽  
Martin FLÖRCHINGER ◽  
H. Ekkehard NEUHAUS ◽  
Torsten MÖHLMANN

Research on metabolism of nucleotides and their derivatives has gained increasing interest in the recent past. This includes de novo synthesis, analysis of salvage pathways, breakdown and transport of nucleotides, nucleosides and nucleobases. To perform a further step towards the analysis of nucleoside transport in Arabidopsis, we incubated leaf discs with various radioactively labelled nucleosides. Leaf cells imported labelled nucleosides and incorporated these compounds into RNA, but not into DNA. Furthermore, we report on the biochemical properties of three so far uncharacterized members of the Arabidopsis ENT (equilibrative nucleoside transporter) family (AtENT4, AtENT6 and AtENT7). After heterologous expression in yeast, all three proteins exhibited broad substrate specificity and transported the purine nucleosides adenosine and guanosine, as well as the pyrimidine nucleosides cytidine and uridine. The apparent Km values were in the range 3–94 μM, and transport was inhibited most strongly by deoxynucleosides, and to a smaller extent by nucleobases. Typical inhibitors of mammalian ENT proteins, such as dilazep and NBMPR (nitrobenzylmercaptopurine ribonucleoside, also known as nitrobenzylthioinosine) surprisingly exerted almost no effect on Arabidopsis ENT proteins. Transport mediated by the AtENT isoforms differed in pH-dependency, e.g. AtENT7 was not affected by changes in pH, AtENT3, 4 and 6 exhibited a less pronounced pH-dependency, and AtENT1 activity was clearly pH-dependent. Using a GFP (green fluorescent protein)-fusion protein transiently expressed in tobacco leaf protoplasts, a localization of AtENT6 in the plant plasma membrane has been revealed.


2017 ◽  
Vol 32 (2) ◽  
pp. 151-156 ◽  
Author(s):  
Akinori Takagi ◽  
Tomohiro Nishimura ◽  
Tomoya Akashi ◽  
Masatoshi Tomi ◽  
Emi Nakashima

2021 ◽  
Author(s):  
Weidong Fei ◽  
Yunchun Zhao ◽  
Xiaodong Wu ◽  
Dongli Sun ◽  
Yao Yao ◽  
...  

Abstract The gestational trophoblastic tumor seriously endangers child productive needs and the health of women in childbearing age. Nanodrug-based therapy mediated by transporters provides novel strategy for the treatment of trophoblastic tumors. Focus on the overexpressed human equilibrative nucleoside transporter 1 (ENT1) on the membrane of choriocarcinoma cells (JEG-3), the cytarabine (Cy, a substrate of ENT1) grafted liposome (Cy-Lipo) was introduced for targeted delivery of methotrexate (Cy-Lipo@MTX) for choriocarcinoma therapy in this study. The ENT1 has high affinity for Cy-Lipo and can mediate the endocytosis of the designed nanovehicles into JEG-3 cells. The ENT1 protein maintains its transporting function through circulation and regeneration during endocytosis. Therefore, Cy-Lipo-based formulations achieved high tumor accumulation and retention in pharmacokinetic and distribution studies. More importantly, the designed Cy-lipid conjugation exhibited a synergistic therapeutic effect on choriocarcinoma. Finally, Cy-Lipo@MTX exerts an extremely powerful anti-choriocarcinoma effect with fewer side effects. This study suggests that the overexpressed ENT1 on choriocarcinoma cells holds a great potential to be a high-efficiency target for the rational design of active targeting nanotherapeutics.


2016 ◽  
Vol 37 (6) ◽  
pp. 336-344 ◽  
Author(s):  
Christopher J. Endres ◽  
Aaron M. Moss ◽  
Kazuya Ishida ◽  
Rajgopal Govindarajan ◽  
Jashvant D. Unadkat

Sign in / Sign up

Export Citation Format

Share Document